{"schemaVersion":1,"profileUrl":"https://nowen.ai/agents/flowneuroscience-com","markdownUrl":"https://nowen.ai/agents/flowneuroscience-com.md","jsonUrl":"https://nowen.ai/agents/flowneuroscience-com.json","name":"Flow Neuroscience","nickname":"Flow","website":"https://www.flowneuroscience.com","industry":"Medical Devices","status":{"trust":"unclaimed","text":"Unclaimed: compiled by Nowen from public sources, not reviewed by the company"},"updatedAt":"2026-09-06T23:22:14.005Z","summary":"Flow Neuroscience develops FDA-approved at-home neuromodulation therapies for adults with depression.","description":"Flow Neuroscience develops at-home neuromodulation solutions to treat depression. The company offers FDA-approved, home-based neuromodulation therapy for adults with major depressive disorder, usable as a standalone treatment or alongside other therapies. The organization aims to increase accessibility to effective depression care and support clinicians with safe, science-backed treatment options.","mission":"To provide accessible, evidence-based, FDA-approved neuromodulation treatments for people living with depression.","directory":{"industryName":"Medical Devices","agentCount":21,"indexable":true,"hubUrl":"https://nowen.ai/industry/medical-devices"},"aiReaderFamilies":["Perplexity","Amazon"],"products":[{"name":"Flow FL-100","type":"Product","url":"https://www.flowneuroscience.com/efficacy-and-outcomes-flow-neuroscience?hsLang=en-us","summary":"FDA-approved at-home treatment for depression offered as monotherapy or adjunct therapy.","description":"Flow FL-100 is an FDA-approved, home-based neuromodulation treatment for adults 18 and older with moderate to severe Major Depressive Disorder. It can be used as a monotherapy or as an adjunct to antidepressant therapy, without requiring prior medication failure. The device is designed for at-home use and supports Flow Neuroscience’s aim to broaden access to effective depression care. Evidence from a multisite, double-blind, randomized trial shows Flow FL-100 is effective when used as both a standalone treatment and an adjunct to antidepressant therapy at 10 weeks. Real-world data from over 40,000 users indicate a favorable safety profile with a low incidence of adverse reactions (4.5%).","pricing":{},"features":[{"name":"10-week trial evidence","value":"Demonstrates Proven Effectiveness","valueDescription":"Results from a rigorous clinical trial validate the efficacy of Flow FL-100 as both a standalone treatment and when used alongside traditional antidepressants."},{"name":"At-home neuromodulation","value":"Enables At-Home Treatment","valueDescription":"Facilitates convenient access to depression treatment within the comfort of home, improving adherence and comfort."},{"name":"Crisis care evaluation results","value":"Significantly Reduces Suicidal Ideation","valueDescription":"Demonstrates the potential of Flow FL-100 in providing critical support for individuals in crisis."},{"name":"Adults 18 and older","value":"Targets Adult Population","valueDescription":"Specifically designed to meet the needs of adults suffering from significant depressive symptoms."},{"name":"Monotherapy or adjunct therapy option","value":"Offers Treatment Flexibility","valueDescription":"Provides a versatile treatment approach that accommodates varying patient needs and treatment histories."},{"name":"Favorable safety profile","value":"Ensures Safety During Use","valueDescription":"Data suggest a minimal risk of side effects, supporting its safety for users."},{"name":"US availability timeline","value":"Awareness of Upcoming Launch","valueDescription":"Keeps potential users informed about the anticipated timeline for accessing this innovative treatment in the U.S."}]}],"audiences":[],"segments":[{"name":"At-home neuromodulation for major depressive disorder","description":"Home-administered, FDA-approved neuromodulation therapy for adults with moderate to severe major depressive disorder that can be used as monotherapy or adjunctive treatment to expand access to evidence-based care.","color":1,"productNames":["Flow FL-100"]},{"name":"Prescription neuromodulation devices for clinical practice","description":"Clinician-prescribed neuromodulation devices integrated into outpatient care pathways for depression, supported by randomized trial evidence and real-world safety data to inform treatment planning.","color":2,"productNames":["Flow FL-100"]},{"name":"Adjunctive treatment to antidepressant therapy","description":"Therapies used alongside antidepressant medications to improve clinical response and reduce suicidal ideation, backed by clinical trial and real-world outcome data.","color":3,"productNames":["Flow FL-100"]},{"name":"Remote depression care and maintenance therapy","description":"Remote-managed, home-based interventions for ongoing symptom management and maintenance treatment to improve continuity of care and access for adults with MDD, informed by real-world user data.","color":4,"productNames":["Flow FL-100"]}],"faq":[],"comparisons":[],"sources":[{"url":"https://www.flowneuroscience.com","text":"Flow Neuroscience"},{"url":"https://www.flowneuroscience.com/efficacy-and-outcomes-flow-neuroscience?hsLang=en-us","text":"Flow FL-100"}]}